Evidence map›Paper›PMID 36316039›Full record

ArticleCancer genomics & proteomics

Oral Installation of Recombinant Methioninase-producing

Yutaro Kubota, Qinghong Han, Kazuyuki Hamada, Yusuke Aoki, Noriyuki Masaki, Koya Obara, Anton Baranov, Michael Bouvet, Takuya Tsunoda, Robert M Hoffman

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Recombinant-methioninase-producingCancer diagnosis & prognosis
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yutaro KubotaAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Kazuyuki HamadaAntiCancer Inc., San Diego, CA, U.S.A.
Yusuke AokiAntiCancer Inc., San Diego, CA, U.S.A.
Noriyuki MasakiAntiCancer Inc., San Diego, CA, U.S.A.
Koya ObaraAntiCancer Inc., San Diego, CA, U.S.A.
Anton BaranovAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Takuya TsunodaDivision of Internal Medicine, Department of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.
University of California, San Diego · USAntiCancer (United States) · USShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAll cancer types so far tested are methionine-addicted. Targeting the methionine addiction of cancer with recombinant methioninase (rMETase) has shown great progress in vitro, in mouse models, and in the clinic. However, administration of rMETase requires multiple doses per day. In the present study, we determined if rMETase-producing Escherichia coli JM109 (E. coli JM109-rMETase) might be an effective anticancer agent when installed into the microbiome. MATERIALS AND

methodsE. coli JM109-rMETase was administered to a syngeneic model of MC38 colon cancer growing subcutaneously in C57BL/6 mice. JM109-rMETase was administered orally by gavage to the mice twice per day. Tumor size was measured with calipers.

resultsThe administration of E. coli JM109-rMETase twice a day significantly inhibited MC38 colon-cancer growth. E. coli JM109-rMETase was found in the stool of treated mice, indicating it had entered the microbiome.

conclusionThe present study indicates the potential of microbiome-based treatment of cancer targeting methionine addiction.

Indexed as

Colonic NeoplasmsMicrobiotaAnimalsCarbon-Sulfur LyasesDisease Models, AnimalEscherichia coliMethionineMiceMice, Inbred C57BLMice, NudeRecombinant ProteinsCarbon-Sulfur LyasesL-methionine gamma-lyaseMethionineRecombinant Proteinscolon cancerEscherichia coliHoffman effectmethionine addictionmicrobiomeRecombinant methioninasesyngeneic mouse model

Identifiers

PMID36316039
PMCPMC9620449
OpenAlexW4308189789

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.